BioAtla enters $100M ATM equity offering with Jefferies

BioAtla, Inc.

Up to $100M aggregate gross sales proceeds from common stock sold through Jefferies as sales agent.
Jefferies will receive 3% commission on gross proceeds; company reimburses certain expenses.
Company has no obligation to sell shares; may suspend offering at any time.
Shares issued under existing effective shelf registration statement (File No. 333-262528).
Offering terminates upon sale of all shares or termination of agreement.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BioAtla, Inc. entered into Sales Agreement with Jefferies LLC valued at up to $100,000,000 (effective 2023-01-06).

Action: entry
Agreement: atm program
Counterparty: Jefferies LLC
Value: up to $100,000,000
Effective: 2023-01-06

Exact text from the filing

On January 6, 2023, BioAtla, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) under which the Company may offer and sell, from time to time in its sole discretion, shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), with aggregate gross sales proceeds of up to $100,000,000 through an “at the market” equity offering program under which Jefferies will act as sales agent.

View on SEC.gov

Browse all material agreements →

BioAtla, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-003550

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.